Clinical Trials at Tennessee Oncology

As of July 2026, 55 paid clinical trials are recruiting at Tennessee Oncology, located at Tennessee Oncology PLLC: PET-Nashville, 322 22nd Ave N Suite 140, Nashville, TN 37203, phone (615) 320-7387 in Nashville, Tennessee. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 10, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

55 clinical trials at Tennessee Oncology

·Clear filters·↓ Download CSV

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

for Relapsed/Refractory Multiple Myeloma

16 locations incl. Birmingham

Sponsor: Caribou Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05722418·Phase 1·Recruiting

Apply to this trial

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

for Relapsed and/or Refractory Multiple Myeloma

13 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06153251·Phase 1·Recruiting

Apply to this trial

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

for Non Small Cell Lung Cancer

9 locations incl. Margate

Sponsor: Compass Therapeutics

Sex: All·Age: 18+

Code: NCT06150664·Phase 1·Recruiting

Apply to this trial

A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

for Colorectal Neoplasms

4 locations incl. Sarasota

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT07107230·Phase 1·Recruiting

Apply to this trial

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

for Advanced Solid Tumors

Drug: Ivonescimab

6 locations incl. Norwich

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07397338·Phase 1, Phase 2·Recruiting

Apply to this trial

IKS014 in Advanced Solid Tumors That Express HER2

for Breast Cancer

4 locations incl. Newport Beach

Sponsor: Iksuda Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT05872295·Phase 1·Recruiting

Apply to this trial

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

for Colorectal Cancer

3 locations incl. Duarte

Sponsor: Dispatch Biotherapeutics

Sex: All·Age: 18+

Code: NCT07544589·Phase 1·Recruiting

Apply to this trial

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

for Ovarian Cancer

5 locations incl. Peoria

Sponsor: Nerviano Medical Sciences

Sex: Female·Age: 18+

Code: NCT06930755·Phase 1·Recruiting

Apply to this trial

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

for Locally Advanced or Metastatic Malignant Solid Tumors

4 locations incl. Hackensack

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT07287995·Phase 1, Phase 2·Recruiting

Apply to this trial

A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells

for Long Term Safety Following GM T Cell Therapy

1 location in Nashville

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06798298·Recruiting

Apply to this trial

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

for Advanced Solid Tumor, Adult

6 locations incl. Grand Rapids

Sponsor: Cogent Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT07361562·Phase 1·Recruiting

Apply to this trial

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

for Non-Hodgkin Lymphoma Refractory/ Relapsed

5 locations incl. Duarte

Sponsor: LTZ Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07121946·Phase 1·Recruiting

Apply to this trial

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

for Relapsed/Refractory B-cell Malignancies

9 locations incl. Denver

Sponsor: Accutar Biotechnology Inc

Sex: All·Age: 18+

Code: NCT05780034·Phase 1·Recruiting

Apply to this trial

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

for Advanced Solid Tumors

7 locations incl. Los Angeles

Sponsor: LigaChem Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05941507·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

for Breast Cancer

8 locations incl. Columbia

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05748834·Phase 2·Recruiting

Apply to this trial